Current means for identifying the latent stage of a neurodegenerative process
A characteristic feature of neurodegenerative diseases is thepresence of a long-term latent stage, while manifestation ofsymptoms occurs after 4060% cells loss in vulnerable neuronpopulations. Therefore, potential for neuroprotection is maximaljust at the latent stage of the process. In this paper,...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center of Neurology
2017-02-01
|
| Series: | Анналы клинической и экспериментальной неврологии |
| Subjects: | |
| Online Access: | https://annaly-nevrologii.com/journal/pathID/article/viewFile/236/72 |
| Summary: | A characteristic feature of neurodegenerative diseases is thepresence of a long-term latent stage, while manifestation ofsymptoms occurs after 4060% cells loss in vulnerable neuronpopulations. Therefore, potential for neuroprotection is maximaljust at the latent stage of the process. In this paper, currenttechnologies of presymptomatic diagnosis of the two most commonneurodegenerative disorders, Alzheimers and Parkinsons
disease, are presented. On the basis of our own experience anddata from the literature it is shown that neuroimaging methods(identification of beta-amyloid in the brain, or phenomenon ofhyperechogenecity of the s.nigra, etc) in combination with anumber of neurophysiological and molecular/pathobiochemicaltests are principal in revealing persons with high risk of these disorders.Validation of biomarkers under discussion and their integration
into uniform diagnostic screening algorithms is at presentone of the most actual fields of neurology. |
|---|---|
| ISSN: | 2075-5473 2409-2533 |